Paradigm Biocapital Advisors SC 13G Corbus Pharmaceuticals / Paradigm Biocapital Advisors ownership change

Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Corbus Pharmaceuticals Holdings, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned hereby execute this Agreement.

Dated: February 5, 2024

Paradigm BioCapital Advisors LP

Paradigm BioCapital Advisors GP LLC

Paradigm BioCapital International Fund Ltd.

By:   /s/ David K. Kim

Name: David K. Kim

Title: Authorized Signatory

/s/ Senai Asefaw, M.D.

Senai Asefaw, M.D.